Home › Compound Library › Methoxetamine (MXE)

Methoxetamine (MXE)

Dissociativeoral · inferred

Designer arylcyclohexylamine dissociative and NMDA receptor antagonist (Ki = 257 nM at PCP site). Structural analog of ketamine with longer duration (3-5h vs 1-1.5h) and greater potency. Also exhibits significant serotonin reuptake inhibition unlike ketamine. Brain:serum ratio of 2-3x indicates extensive CNS accumulation. Associated with urinary tract toxicity similar to ketamine with chronic use.

Projected serum levels — 20 mg, as needed (shown daily)

Methoxetamine (MXE)
Methoxetamine (MXE) modeled serum levels, 20 mg as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 4 days. 0 12.5 25 37.5 50 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 4
Methoxetamine (MXE) modeled serum levels with a loading dose of 45.6 mg, then 20 mg as needed (shown daily) The first dose is larger so levels approach steady state faster. 0 12.5 25 37.5 50 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 20 mg as needed (shown daily) (oral).

Loading schedule: 45.6 mg on day 1, then 20 mg as needed (shown daily) — reaching therapeutic levels sooner.

Modeled steady state after ~4 days: peak ≈ 29.2 mg, trough ≈ 18.0 mg body load. Population-based estimate over 15 days for a 20 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Dissociative
Route modeled
Oral
Model confidence
inferred
Half-life
29 h
Common dose
20 mg
Reference dose range
10–40 mg (single dose)
Suggested cadence
as needed (shown daily)

Documented interactions

  • contraindicated
    Efavirenz (Sustiva) + Methoxetamine (MXE) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Methoxetamine (MXE) AUC by ~0.16x

  • contraindicated
    Rifampin + Methoxetamine (MXE) CYP induction

    Rifampin inducer of CYP3A4 predicted to change Methoxetamine (MXE) AUC by ~0.16x

  • danger
    1P-LSD (1-Propionyl-LSD) + Methoxetamine (MXE) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and Methoxetamine (MXE) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + Methoxetamine (MXE) Serotonin risk

    25I-NBOMe and Methoxetamine (MXE) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Methoxetamine (MXE) Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Methoxetamine (MXE) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Methoxetamine (MXE) Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Methoxetamine (MXE) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 188 modeled interaction pairings for methoxetamine (mxe) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue — Behavioural, pharmacokinetic and metabolic studies in the Wistar rat Horsley RR et al. · European Neuropsychopharmacology, 2016 DOI

    Comprehensive preclinical PK study showing MXE brain levels peak at 30 min, brain:serum ratio of 2.06-2.93, and progressive decline to near-zero at 6 hours.

  2. From "Special K" to "Special M": The Evolution of the Recreational Use of Ketamine and Methoxetamine Zanda MT et al. · CNS Neuroscience & Therapeutics, 2019 DOI

    Review comparing ketamine and MXE pharmacology, highlighting MXE higher NMDA affinity, additional serotonergic activity, and longer duration of action.

2 published studies referenced in the app, each with a plain-language summary.